Showing 1971-1980 of 9336 results for "".
- Galderma and Aklief Unveil "Me Being Me" Campaign, Survey Results on Acne Zoom Burdenhttps://practicaldermatology.com/news/galderma-and-aklief-unveil-me-being-me-campaign-survey-results-on-acne-zoom-burden/2460703/Galderma Laboratories, L.P. and Aklief (trifarotene) Cream, 0.005% are launching Me Being Me, a new consumer campaign that was crafted in response to today’s increasingly digital-focused world. The campaign is designed to inspire those living with acne to feel confident in their own skin by sharin…
- ASDSA, Northwestern University Introduce Cutaneous Procedures Adverse Events Reporting (CAPER) Systemhttps://practicaldermatology.com/news/asds-northwestern-university-introduce-cutaneous-procedures-adverse-events-reporting-caper-system/2460701/The American Society for Dermatologic Surgery Association (ASDSA) and the Northwestern University Department of Dermatology are launching the Cutaneous Procedures Adverse Events Reporting (CAPER) system. This voluntary reporting system gathers patients’ adverse events (AEs) encountered during derm…
- With sNDA, Amgen Seeks Approval for Otezla in Mild-to-Moderate PsOhttps://practicaldermatology.com/news/with-snda-amgen-seeks-approval-for-otezla-in-mild-to-moderate-pso/2460700/Amgen has submitted a supplemental New Drug Application (sNDA) to the FDA for Otezla® (apremilast) for the treatment of adults with mild-to-moderate plaque psoriasis who are candidates for phototherapy or systemic therapy. The sNDA is based on data from the Phase 3 ADVANCE trial that demonstrated o…
- Label Update: Simponi Aria Improves Fatigue in PsA, RAhttps://practicaldermatology.com/news/label-update-simponi-aria-improves-fatigue-in-psa-ra/2460699/Simponi Aria (golimumab) from Janssen Pharmaceutical Company of Johnson & Johnson is the first and only fully human anti-tumor necrosis factor (TNF) biologic approved by the FDA to include language in its product label stating that the treatment results in improvement in fatigue for adult patients …
- Five-Year Data for Ilumya Show Long-term Efficacy, Safetyhttps://practicaldermatology.com/news/five-year-data-for-ilumya-show-long-term-efficacy-safety/2460698/Long-term data from Phase 3 extension trials for Sun Pharma’s Ilumya (tildrakizumab) in psoriasis show the treatment provided sustained disease control over five years among subjects who were week 28 tildrakizumab responders and etanercept partial responders/nonresponders. Ilumya provided a durable…
- AbbVie, Evolus Agree to Settlementhttps://practicaldermatology.com/news/abbvie-evolus-agree-to-settlement/2460697/AbbVie, Evolus, and Medytox have agreed to a new settlement to fully resolve all outstanding litigation, including the US International Trade Commission (ITC) case regarding the sale of Jeuveau®, between the companies. A California court case filed by Medytox against Evolus will be dismissed. Unde…
- Researchers Identify Mechanisms That Are Essential for Proper Skin Developmenthttps://practicaldermatology.com/news/researchers-identify-mechanisms-that-are-essential-for-proper-skin-development/2460696/Mount Sinai researchers have discovered that Polycomb complexes, groups of proteins that maintain gene expression patterns, are essential for proper skin development, according to a paper published in Genes & Development. This discovery could improve development of future stem cell therapies to …
- Almirall, MC2 Therapeutics Strike Deal to Distribute Wynzora in Europehttps://practicaldermatology.com/news/almirall-mc2-therapeutics-strike-deal-to-distribute-wynzora-in-europe/2460692/Under a new agreement, MC2 Therapeutics has granted Almirall SA exclusive European rights to commercialize Wynzora® Cream for treatment of plaque psoriasis. In exchange, MC2 Therapeutics is eligible to receive upfront to launch payments of EUR 15 million in addition to significant sales milestone p…
- DermTech Adds to Scientific Advisory Boardhttps://practicaldermatology.com/news/dermtech-adds-to-scientific-advisory-board/2460686/Drs. Lisa Beck and George Han are the newest members of DermTech’s Scientific Advisory Board, Lisa Beck, MD, is the co-director of the University of Rochester Medical Center for Allergic Disease Research and has served on the board of directors of the International Eczema Council since 2014. Speci…
- Ortho Dermatologics Opens Applications for 2021 Aspire Higher Scholarship Programhttps://practicaldermatology.com/news/ortho-dermatologics-opens-applications-for-2021-aspire-higher-scholarship-program/2460683/Ortho Dermatologics opened the application process for its 2021 Aspire Higher scholarship program. The program, which began in 2013, will award nine students who have been treated for a dermatologic condition with a scholarship of up to $10,000 in support of their academic goals. “Many students to…